Engineering the Future of Medicine: The Evolution of Monoclonal Antibody (mAb) Therapeutics

Abstract

Background: Monoclonal antibodies (mAbs) have become one of the most successful classes of biopharmaceuticals, revolutionizing the treatment of cancer, autoimmune disorders, infectious diseases, and numerous chronic conditions. Since the introduction of hybridoma technology in 1975, continuous advances in antibody engineering have dramatically improved antibody specificity, efficacy, safety, and clinical applicability. Main Findings: This review summarizes the historical evolution of monoclonal antibody therapeutics, highlighting the major technological advances that have driven the transition from murine antibodies to humanized and fully human antibody platforms. Recent innovations, including Fc (fragment crystallizable) engineering to enhance antibody half-life and immune effector functions, glycoengineering, bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and artificial intelligence-assisted antibody discovery, have significantly expanded the therapeutic potential of monoclonal antibodies while addressing many limitations associated with earlier generations. Furthermore, advances in biomanufacturing technologies, computational biology, and precision medicine have accelerated antibody discovery and development, improved production efficiency, and broadened the clinical application of monoclonal antibody therapeutics across a wide range of diseases. Future Perspectives: Future progress is expected to rely on integrating synthetic biology, machine learning, structural bioinformatics, and next-generation protein engineering to develop safer, more effective, and increasingly personalized antibody therapeutics. Continued improvements in manufacturing efficiency, target selection, and combination treatment strategies are anticipated to further establish monoclonal antibodies as central components of precision medicine and next-generation healthcare.